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ABSTRAK
Resistensi insulin merupakan gangguan dalam regulasi glukosa yang ditandai dengan peningkatan kadar 
insulin. Dalam konteks klinik, resistensi insulin dapat bermanifestasi sebagai sindrom metabolik yang memiliki 
risiko kejadian kardivaskular yang tinggi. Beberapa studi telah melaporkan bahwa resistensi insulin berhubungan 
langsung terhadap adanya esofagitis erosif pada pasien dengan penyakit refluks gastroesofageal (GERD). Dalam 
tinjauan pustaka ini, kami akan menelaah pemahaman terbaru yang dapat menjelaskan adanya resistensi insulin 
pada pasien dengan penyakit refluks gastroesofageal.
Kata kunci: resistensi insulin, GERD, sindrom metabolik, esofagitis erosif.
ABSTRACT
Insulin resistance is the disturbance of glucose regulation characterized by higher insulin level. In clinical 
context, insulin resistance can manifest as abnormalities that are related with cardiovascular event risk, known as 
metabolic syndrome. Several studies had reported that insulin resistance was associated with erosive esophagitis 
in patients with gastroesophageal reflux disease (GERD).
Keywords: insulin resistance, GERD, metabolic syndrome, erosive esophagitis.
INTRODUCTION
Insulin sensitivity is the ability of insulin 
to exert normal physiologic effects in glucose 
regulation. In clinical context, insulin resistance 
may manifest as obesity, dyslipidemia, and 
hyperglycemia. These related abnormalities 
carry high risk of cardiovascular events, known 
as metabolic syndrome.1,2
The rising prevalence of metabolic syndrome 
carries a public health issue that needs attention. 
Based on Riskesdas 2013, the proportion of 
high triglyceride levels in Indonesia, low HDL, 
and hypertension had reached 13%, 22.9%, and 
25.8%, respectively.3 A survey in Jakarta in 
2006 showed that the prevalence of metabolic 
syndrome had reached 28.6%.4
In addition to the risk of cardiovascular 
events, insulin resistance may also be associated 
with other conditions such as polycystic 
ovary syndrome, non-alcoholic fatty liver 
disease, and gastroesophageal reflux disease.1 
Gastroesophageal Reflux Disease (GERD) is 
quite common in daily practice. The prevalence 
of GERD in Jakarta in 2002 was 25.18%.5 This 
disease has a wide clinical spectrum and may 
cause complications related to gastric reflux to 
the esophagus, oral cavity, and / or lung and are 
associated with decreased quality of life.6,7 This 
paper will discuss the current understanding of 
the relationship between gastroesophageal reflux 
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disease and insulin resistance.
I N S U L I N  R E S I S TA N C E  A N D  I T S 
MECHANISM
Insulin sensitivity is the ability of insulin to 
work in glucose regulation, to increase glucose 
absorption, lower glucose levels and increase 
the conversion of glucose into a form that is 
stored by the body. Insulin resistance can be 
defined as decreased tissue responsiveness to 
insulin with an increased production of insulin 
to provide a normal biological response. Insulin 
resistance syndrome is a group of abnormalities 
and interrelated physical manifestations that 
occur in individuals with insulin resistance. 
Meanwhile, the metabolic syndrome represents a 
clinical diagnostic entity associated with insulin 
resistance that identifies an individual as having 
a high risk of cardiovascular morbidity.1
Under normal circumstances, insulin release 
from pancreatic β cells will induce the entry 
of glucose into cells when binding to insulin 
receptors on the cell surface. The insulin receptor 
will undergo autophosphorylation initiating 
a cascade in the translocation of glucose 
transporters types 1 and 4 (GLUT 1 and GLUT 
4) to the membrane in facilitating the entry 
of glucose into the cell.8.9 The circumstances 
that cause insulin receptor disorders, both in 
activity and concentration, will affect the action 
of insulin. Molecular mechanism disturbances 
associated with glucose transport activity through 
insulin receptor substrate serine phosphorylation 
(IRS) -1 and mitochondrial disorders may cause 
insulin resistance.8
The mechanisms of insulin resistance in 
obesity begin with increased fatty acyl CoA 
and diacylglycerol in plasma and / or decreased 
oxidation due to mitochondrial dysfunction that 
activates protein kinase C in skeletal muscle. 
Furthermore, activation of serine residue on 
IRS-1 will decrease GLUT4 translocation. 
In the liver, elevated hepatic diacylglycerol 
content due to increased fatty acids from 
plasma will lead to decreased insulin kinase 
receptor activity and decrease IRS-2 tyrosine 
phosphorylase, resulting in decreased insulin 
stimulation of glycogen synthase activation 
and decreased phosphorylation of forkhead box 
protein O (FOXO) which may elevate hepatic 
gluconeogenesis.8-10
When there is an increase in adipocytes, 
especially abdominal visceral fat, the body’s 
insulin sensitivity decreases. The target tissue 
reduces the number of insulin receptors on 
the cell surface in response to prolonged high 
insulin levels. Adipose tissue can affect insulin 
sensitivity to other tissues by secreting adipokine 
molecules (TNFα, IL-6) that inhibit insulin 
signals locally or on remote target tissues.11
Measurement of Insulin Resistance
Insulin resistance is measured by two 
approaches, dynamic intervention and steady 
state assessment using mathematical calculations. 
The first approach includes examination of 
hyperinsulinemic glucose clamp, which is 
the gold standard. While the second approach 
includes assessment of Homeostasis Model 
Assessment for Insulin Resistance (HOMA-
IR) and quantitative insulin sensitivity check 
index (QUICKI). This calculation is processed 
using a mathematical formula that represents 
fasting insulin kinetic and fasting glucose 
measurement.12
This mathematical equation was often used 
in epidemiology study due to the practical 
and easy method using one blood sample. 
Nevertheless, this simple method could not 
be used in determining insulin resistance in 
certain population, such as in elderly and type 
1 diabetes. This is due to insulin levels that 
will not accurately represent insulin resistance 
because β cells do not secrete sufficient insulin.12 
Nevertheless, in one multivariate study in 
patients with hypertension and type 2 diabetes 
mellitus comparing HOMA-IR, QUICKI and 
McAulay index against insulin resistance using 
clamp technique, HOMA IR and QUICKI had 
good validity in estimating insulin resistance, 
with HOMA IR was being the most appropriate 
value.13 In addition, there was a good correlation 
between the estimated value of insulin resistance 
from HOMA and from the Clamp technique.8
The model of insulin resistance homeostasis 
(HOMA-IR) is used to estimate insulin resistance 
and β cell function using plasma insulin and 
fasting glucose concentration. The relationship 
between glucose and insulin in the basal state 
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reflects the balance between liver glucose output 
and insulin secretion maintained by the feedback 
mechanism between the liver and β cells. There is 
no cut off value that applied globally to determine 
insulin resistance. The higher the HOMA-IR 
index, the higher the insulin resistance in one 
individual.11,13 One study in Japan determined 
the value of HOMA-IR > 1.7 as a reference point 
for identifying subjects with a high risk of the 
presence of the metabolic syndrome.14 Indonesia 
does not have data on the average value of insulin 
resistance in the general population, but study in 
obese adolescents revealed HOMA-IR mean was 
3.92 and in elderly women had a mean HOMA-
IR level of 2.87.15,16
GASTROESOPHAGEAL REFLUX DISEASE
Gastroesophageal reflux disease (GERD) 
is defined as symptoms of reflux or mucosal 
damage due to reflux of gastric contents into the 
esophagus or higher, to the oral or lung cavity, 
causing symptoms or related complications. 
This gastroesophageal reflux disease may be 
classified as a non-erosive reflux disease (NERD) 
or erosive reflux disease (ERD) based on the 
presence or absence of esophageal mucosal 
damage seen in endoscopy.5-7
Epidemiological studies in western countries 
show that the prevalence of GERD was higher 
(10-20%) than Asian countries (3-5%). Disturbing 
heartburn symptoms were seen in about 6% of 
the population and regurgitation reached 16% of 
the population above.7,17 Indonesia does not have 
national epidemiological data on the disease. 
Endoscopic studies at RSCM / FKUI involving 
1718 dyspepsia patients from 1997 to 2002 found 
an increase in esophageal prevalence of 5.7% in 
1997 to 25.18% in 2002.5 Another study in the 
general population in Depok in 2012 showed 
the prevalence of GERD using a GERD-Q 
questionnaire was 9.35%.18 However, recent 
study in 2016 among population of physicians in 
Indonesia, showed that the prevalence of GERD 
was 27.4%.19
Reflux is a normal physiologic incident 
and is caused by the transient relaxation of the 
lower esophageal sphincter (LES). Under normal 
circumstances, there is an endogenous defense 
mechanism, the action of LES that inhibit 
irritating substance entering the esophagus, and 
the mechanism of excreting irritating materials 
through normal esophageal motility. If there is 
a disturbance in this defense mechanism, the 
esophagus will be irritated by prolonged acidic 
liquids, resulting in GERD conditions. In patients 
with GERD, temporary relaxation of LES 
occurs more frequently than normal conditions. 
Defects in LES, such as hypotonicity in LES, 
and the effects of a hiatal hernia can cause the 
condition.20,21
I N S U L I N  R E S I S T A N C E  A N D 
GASTROESOFAGEAL REFLUX DISEASE
There are many studies that linking 
gastroesophageal reflux disease with metabolic 
syndrome. A study by Park et al.22 showed an 
association between erosive esophagitis and 
metabolic syndrome.Another study by Wu et 
al.23 showed that the prevalence of metabolic 
syndrome in patients with reflux esophagitis 
was significantly higher than that of the control 
group and parameters associated with reflux 
esophagitis were peripheral circumference, and 
fasting blood glucose.
Hyperglycemia is a consequence of insulin 
resistance. It is known that the mechanism of 
GERD is primarily caused by a disturbance in the 
lower esophageal sphincter (LES). The relationship 
between fasting blood glucose and GERD 
symptoms can be explained by the presence of 
interference from the sensory and motor function 
of the esophagus. Changes in motility resulting 
from hyperglycemia include increased duration of 
peristaltic waves and decreased peristaltic velocity 
in the distal esophagus, decreased LES pressure, 
and deceleration of gastric emptying.24,25 In 
diabetic patients, hyperglycemia is associated with 
prolonged LES relaxation period compared with 
euglycemic patients.24.26 In normal individuals, 
hyperglycemia will decrease the lower esophageal 
sphincter pressure and esophageal peristalsis 
acceleration. In addition, the amount of temporary 
sphincter relaxation increases in hyperglycemic 
conditions.27
The component of metabolic syndrome that 
has been extensively studied in relation to GERD 
is obesity. The point that needs to be emphasized 
is that obesity is not a consequence of insulin 
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resistance, but a variable that can decrease insulin 
action against glucose regulation.28 Obesity is an 
independent risk factor for GERD, particularly 
esophageal erosion. The main mechanism is 
related to temporary relaxation in LES. There are 
several factors that cause GERD in obese patients, 
including increased gastroesophageal sphincter 
gradient, hiatal hernia incidence, intraabdominal 
pressure, and pancreatic and bile enzyme output.23 
Hiatal hernia is the protrusion of the stomach 
through the diaphragm gap that can increase 
GERD incidence through weak LES tone and 
lower LES pressure at rest, as well as slower acid 
emptying than individuals without hiatal hernia. In 
addition to mechanical mechanisms, an increased 
metabolic activity in adipose tissue, especially 
visceral adipose tissue, increases adipokine 
secretion including IL-6 and TNF α which play a 
role in esophageal motility.22,29
The mechanism of esophageal reflux 
associated with cytokines is a cycle that aggravates 
one another. Proinflammatory cytokines such as 
IL-6 and IL-1 produced by adipose tissue can 
decrease esophageal muscle contraction. The 
presence of reflux can lead to further esophagitis 
through the production of cytokines from the 
refluxate that stimulates esophageal epithelial 
cells to produce chemokines that may cause 
damage to the esophageal tissue.30 Activation of 
the inflammatory system will lead to increased 
production of adhesion molecules and other 
cytokines thereby increasing inflammation. In 
addition, endothelial cell activation also increases 
the progression of inflammation. Acid reflux will 
lead to platelet-activating factor (PAF) formation 
which is then released from the mucosa to activate 
circular muscle causing the production of IL-6, 
H2O2, and IL-1β, which is known to decrease 
Figure 1. Proposed mechanism for the association of GERD and insulin resistance
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neurogenic muscle contraction by inhibiting the 
release of acetylcholine.29,30
Insulin resistance can be directly related to 
GERD events. A study by Ming et al. showed that 
insulin resistance had a significant association 
with erosive gastritis, but metabolic syndrome 
was not associated with GERD. This is probably 
due to those conditions which do not always 
coincide.31 There were several studies about the 
association of GERD with insulin resistance. 
One study in Europe reported that patients 
with Barretts esophagus, a result of long-term 
GERD, had higher insulin resistance than those 
without Barretts esophagus.32 Higher insulin 
resistance was reported to be higher in erosive 
esophagitis than non-erosive esophagitis obese 
population in South Korea.22 Another study in 
the general population in Taiwan also reported 
that insulin resistance was correlated with 
severe reflux disease, based on a validated 
questionnaire in Taiwan.33 In addition, there is a 
study which showed that GERD symptoms and 
HOMA-IR values can be improved with lifestyle 
improvement.34 However, Japanese studies 
have shown that insulin sensitivity is negatively 
correlated with GERD symptoms, but insulin 
resistance has no significant relationship with 
GERD severity.35
The association of insulin resistance and 
gastroesophageal reflux disease are complex 
and the relationship between them can be 
explained by correlating inflammatory mediators. 
Gastroesophageal reflux disease has been shown 
to produce both localized esophageal and systemic 
inflammatory mediators.30,36 Based on studies on 
GERD patients in Moscow, it was found that 
proinflammatory cytokines levels such as IL-8 and 
TNFα in serum patients with erosive esophagitis 
were higher than those without esophagitis or 
normal subjects.36 Proinflammatory cytokines, 
such as IL-6 and TNFα, have been associated 
with insulin resistance through increased serine 
phosphorylation of Insulin Receptor Substrate-1 
(IRS-1) which will eventually inhibit the action 
Figure 2. Cellular mechanism of inflammation associated insulin resistance.39
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of Glucose Transporter Type 4 (GLUT-4).37 
Proinflammatory cytokines have been associated 
with insulin resistance, through the inhibitory 
effect on insulin transport pathways in Tlr-4 
related cells, although the exact mechanism 
is unclear. A study conducted by Fernandez 
et al38 showed a positive correlation between 
IL-6 levels and insulin resistance. Systemic 
inflammatory conditions may cause disruption 
of insulin sensitivity through cellular pathways 
of JNK, and IKKβ / NFκB in adipocytes, 
hepatocytes, and macrophages.39
CONCLUSION
The literature review has consistently shown 
an association between gastroesophageal reflux 
disease, particularly erosive reflux disease, and 
insulin resistance. Their relationship is associated 
with interrelated inflammatory mediators. 
However, the pathophysiology involved is so 
complicated that many possible related factors 
may not be identified yet, such as the cellular 
mechanism associated with inflammatory 
mediators. Therefore, further research and 
literature study are needed to understand the 
relationship between both of them. Given the 
link between GERD and insulin resistance, it 
is recommended that clinical characteristics 
of insulin resistance syndrome or metabolic 
syndrome should be sought in patients with 
GERD, particularly erosive reflux disease, and 
the management given to the patient should 
involve both of these aspects.
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